Jeffrey Neul

VUMC receives $13 million grant to coordinate multisite clinical trial for Rett syndrome treatment

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

Potential Rett syndrome drug shows promising results in phase 3 trial

A potential first-of-its-kind drug to treat the symptoms of Rett syndrome received positive top-line results from a phase 3 trial led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety.

Kennedy Center efforts enhance inclusivity in clinical trials

Following the Vanderbilt Kennedy Center’s (VKC) renewal as a national Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center in 2020, the center underwent a shuffling of their four scientific cores that support basic and applied research on intellectual and developmental disabilities (IDD).

Kennedy Center receives grant to continue as IDDRC

The Vanderbilt Kennedy Center (VKC) has been awarded a $6.8 million, five-year grant to continue as a national Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center (IDDRC).

Treating core Rett syndrome symptoms

A new study published in Neurology reports the drug trofinetide has proven safe and effective in treating core symptoms of Rett syndrome in female children and adolescents.